Using men identified with AS-suitable (GS ≤3+3, ≤T2a PCa) prostate cancer in the ERSPC Rotterdam cohort (1999-2003), they retrospectively reviewed the outcomes of men treated with AS according to the PRIAS protocol (n=223), having had a RP (N=365) or treated with RT (n=312).
Table 1 below demonstrates the basic demographics of the three arms. The AM arm is older, has lower initial PSAs, and more likely to be cT1c. The authors acknowledge the unbalanced groups.
With a median follow-up of 15 years (IQR 12-17), they then assessed for cancer-specific survival and metastases-free survival. There were a total of 18 PCa-specific deaths.
Similar to ProtecT, no significant difference in PC specific survival was found between AS, RP and RT (log-rank p=0.36). However, contrary to ProtecT, M+-free survival was also similar amongst the three groups. Table 2 highlights these findings.
While the authors acknowledge that the groups are not evenly matched, they are likely representative of clinical practice. They help confirm what most already suspected from the ProtecT study results.
Speaker(s): J. Verbeek
Co-Authors: Drost F-J., Bangma C., Roobol M.
Institution(s): Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands
Written By: Thenappan Chandrasekar, MD, Clinical Fellow, University of Toronto
at the #EAU17 - March 24-28, 2017- London, England